<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="238">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01216332</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PED 1067</org_study_id>
    <nct_id>NCT01216332</nct_id>
  </id_info>
  <brief_title>Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients</brief_title>
  <official_title>Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High Dose Trivalent Inactivated Influenza Vaccine in Pediatric Patients With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent
      inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with
      Acute Lymphoblastic Leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>To compare safety profile of high dose trivalent inactivated influenza vaccine  to standard dose trivalent inactivated influenza vaccine in pediatric Acute Lymphoblastic Leukemia subjects</measure>
    <time_frame>About 6 months after last dose of vaccine</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare humoral immune responses of pediatric Acute Lymphoblastic Leukemia patients to influenza virus antigens included in trivalent inactivated influenza vaccine after high and standard doses of trivalent inactivated influenza vaccine.</measure>
    <time_frame>About 6 months after last dose of vaccine.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pediatric Patients With Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>High-Dose trivalent inactivated influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose trivalent inactivated influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose trivalent inactivated influenza vaccine</intervention_name>
    <description>0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.</description>
    <arm_group_label>High-Dose trivalent inactivated influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose trivalent inactivated influenza vaccine</intervention_name>
    <description>0.5 mL standard dose trivalent inactivated influenza vaccine</description>
    <arm_group_label>Standard dose trivalent inactivated influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients with standard or high risk Acute Lymphoblastic Leukemia.

          -  Must be in 1st complete remission.

          -  Must be 4 weeks into maintenance therapy.

          -  17 years of age, inclusive.

          -  Available for duration of study.

        Exclusion Criteria:

          -  History of hypersensitivity to previous influenza vaccination or hypersensitivity to
             eggs/egg protein.

          -  History of Guillain-Barre syndrome.

          -  Evidence of relapsed disease.

          -  Have any condition that would, in the opinion of the site investigator, place them at
             an unacceptable risk of injury or render them unable to meet the requirements of the
             protocol.

          -  Have any condition that the investigator believes may interfere with successful
             completion of the study.

          -  History of receiving 2010 - 2011 influenza vaccine.

          -  Pregnant female.

          -  History of proven influenza disease after September 1, 2010.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Halasa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Universtiy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>January 3, 2011</lastchanged_date>
  <firstreceived_date>October 5, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Natasha Halasa, M.D.</name_title>
    <organization>Vanderbilt-Ingram Cancer Center</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
</clinical_study>
